On May 27-28, the Barcelona Science Festival will bring a hundred science activities to the Parc de la Ciutadella.
IRB Barcelona is to participate in the Festival by giving a talk on Network Medicine and holding two workshops for a wide range of public.
During 2017, five activities programmed by the Institute to promote scientific culture will be supported by the FECYT.
Last Saturday IRB Barcelona held its Open Day and received around 400 visitors.
Public of all ages visited the labs, participated in workshops and attended talks at the centre, which is located at the Barcelona Science Park.
The renowned scientist joins the Institute for Research in Biomedicine (IRB Barcelona) after 13 years at CNIO, funded by the “la Caixa” Banking Foundation and by the Government of Catalonia's ICREA programme.
Manuel Serrano will study how damaged tissue is repaired and search for therapies based on regenerative medicine for the treatment of diabetes and other diseases.
From cancer to tissue repair, from CNIO to IRB Barcelona
The project, headed by group leader and ICREA researcher Eduard Batlle, receives a 60,000-€ grant.
The study will test the effectiveness of immunotherapies to treat metastatic disease in advanced colorectal cancer.
Research will take place during the academic years 2017 and 2018.
Prof. Joan J. Guinovart, founder-director of the Institute for Research in Biomedicine (IRB Barcelona) since October 2005, plans to step down from this position early in 2018.
On May 13, IRB Barcelona will be holding its Open Day, from 10:00 to 15:00, and almost all the places have been reserved.
Audiences of all ages will visit the laboratories, participate in workshops, and attend informative talks at the Institute, which is located in the Barcelona Science Park.
In the video "Looking for a needle in a haystack", ICREA researcher at IRB Barcelona describes her work at the front of the Biomedical Genomics laboratory.
The group’s interests range from deciphering the basic biology of cancer to the development of useful tools for the diagnosis and personalised treatment of patients.
In EMBO Molecular Medicine, IRB Barcelona scientists report a technique based on a combination of CRISPR/Cas9 genome editing and patient-derived tumour organoids that allows the study of cell heterogeneity in human tumours.
The novel approach was used to examine the behaviour of colorectal cancer stem cells by tracing specific marker genes.